Interpace Biosciences, Inc. (IDXG) Financials

IDXG Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 33.4 million 10.3 million
Dec. 31, 2025 33.8 million 11.5 million
Sept. 30, 2025 12.0 million 12.3 million
June 30, 2025 12.3 million 13.5 million

IDXG Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 142000 4000
Dec. 31, 2025 2.1 million 43000
Sept. 30, 2025 1.8 million 7000
June 30, 2025 319000 9000

IDXG Net Income

No data available :(

IDXG Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 2.6 million 635000 635000
Dec. 31, 2025 2.5 million 752000 1.2 million
Sept. 30, 2025 1.4 million - 1.3 million
June 30, 2025 502000 - 1.4 million

IDXG Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 ?
Dec. 31, 2025 ?
Sept. 30, 2025 ?
June 30, 2025 ?

IDXG Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 141000 153000 4.6 million 2.2 million
Dec. 31, 2025 38000 142000 4.3 million 2.1 million
Sept. 30, 2025 117000 150000 4.1 million 2.1 million
June 30, 2025 201000 173000 5.6 million 2.9 million

IDXG Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 9.0 million 3.1 million
Dec. 31, 2025 9.2 million 3.2 million
Sept. 30, 2025 8.8 million 3.3 million
June 30, 2025 9.2 million 4.0 million

IDXG Revenue by Segment
Graph available only for paid members. Upgrade to see it.

IDXG

Price: $1.49

52 week price:
0.76
2.40

Earnings Per Share: -0.66 USD

P/E Ratio: -2.70

Exchange: OQX

Sector: Healthcare

Industry: Diagnostics & Research

Country: United States

Volume: 1193

Ebitda: -2.5 million

Market Capitalization: 45.2 million

Links: